MAP2K7 and melanoma: Given the results observed in the C-14401 trial, lifileucel was evaluated in melanoma patients with unresectable/metastatic disease, untreated with ICIs and treated with BRAF/MEK inhibitors if BRAF-mutated, in the context of the IOV-COM-202 clinical study [115].